Pyoderma clinical trials
The registry lists 27 studies for Pyoderma across more than 10 countries. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-08-17.
Status
- Completed
- 13
- Withdrawn
- 4
- Terminated
- 4
- Status unknown
- 3
- Recruiting
- 2
- Not yet recruiting
- 1
Phase
- Phase 2
- 12
- Phase 3
- 5
- Phase 4
- 1
- Phase 1
- 1
- Early Phase 1
- 1
Where
- United States
- 13
- Australia
- 4
- Canada
- 3
- Switzerland
- 2
- Fiji
- 2
- Poland
- 1
Who runs them
XOMA (US) LLC (4) · Oregon Health and Science University (3) · University of Zurich (2) · Wake Forest University Health Sciences (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Valenta Pharm JSC (1) · Dokuz Eylul University (1) · Menzies School of Health Research (1)
Studies
Recruiting first, then most recently updated. Showing 27 of 27 — search for more.
- Efficacy of Bimekizumab in Adults With Pyoderma GangrenosumNot yet recruitingNCT07767864Phase 21 country
- Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)RecruitingNCT06563323Phase 21 country
- A Real-World Registry of Chronic Wounds and UlcersRecruitingNCT022807331 country
- Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)CompletedNCT04901325Phase 21 country
- An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma GangrenosumCompletedNCT03137160Phase 21 country
- Efficacy and Safety of Dioxidin Versus Miramistin in Superficial PyodermaCompletedNCT05561816Phase 31 country
- Exploratory Study of IFX-1 in Patients With Pyoderma GangrenosumCompletedNCT03971643Phase 23 countries
- Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma GangrenosumCompletedNCT02733094Phase 1/21 country
- Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent PyodermaCompletedNCT04895566Early Phase 12 countries
- JAK-STAT Signaling Pathway in Pyoderma GangrenosumStatus unknownNCT04792957
- Safety and Efficacy Study of Humira in Treatment of Pyoderma GangrenosumWithdrawnNCT00730717Phase 21 country
- Efficacy and Safety of APD334 in Patients With Pyoderma GangrenosumTerminatedNCT03072953Phase 22 countries
- Secukinumab for the Inflammatory Phase of Pyoderma GangrenosumWithdrawnNCT04274166Phase 2
- A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in JapanCompletedNCT03311464Phase 31 country
- Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumWithdrawnNCT00690846Phase 21 country
- Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma GangrenosumStatus unknownNCT036367371 country
- Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel DiseaseCompletedNCT00791557Not applicable1 country
- Canakinumab for Pyoderma GangrenosumCompletedNCT01302795Phase 21 country
- Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin DiseasesStatus unknownNCT019522751 country
- An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02326740Phase 33 countries
- An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02315417Phase 31 country
- A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma GangrenosumTerminatedNCT02318914Phase 33 countries
- Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma GangrenosumCompletedNCT01882504Phase 21 country
- Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)WithdrawnNCT00202891Phase 4
- Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern TerritoryCompletedNCT008847281 country
- Streptococcal Infections in Fiji - Prevalence of Group A Streptococcal Pyoderma and Scabies in Infants in FijiCompletedNCT004368911 country
- Prevalence of RHD, Pyoderma and Scabies in Children in FijiCompletedNCT002848431 country